Department of Reconstructive Sciences, University of Connecticut Health Center, Farmington, CT.
Ocean Ophthalmology Group, Miami, FL.
J Prosthodont. 2020 Aug;29(7):599-603. doi: 10.1111/jopr.13220. Epub 2020 Jul 24.
To evaluate the in vitro inactivation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with hydrogen peroxide (H O ) and povidone-iodine (PVP-I) oral antiseptic rinses at clinically recommended concentrations and contact times.
SARS-CoV-2, USA-WA1/2020 strain virus stock was prepared prior to testing by growing in Vero 76 cells. The culture media for prepared virus stock was minimum essential medium (MEM) with 2% fetal bovine serum (FBS) and 50 µg/mL gentamicin. Test compounds consisting of PVP-I oral rinse solutions and H O aqueous solutions were mixed directly with the virus solution so that the final concentration was 50% of the test compound and 50% of the virus solution. Thus PVP-I was tested at concentrations of 0.5%, 1.25%, and 1.5%, and H O was tested at 3% and 1.5% concentrations to represent clinically recommended concentrations. Ethanol and water were evaluated in parallel as standard positive and negative controls. All samples were tested at contact periods of 15 seconds and 30 seconds. Surviving virus from each sample was then quantified by standard end-point dilution assay and the log reduction value of each compound compared to the negative control was calculated.
After the 15-second and 30-second contact times, PVP-I oral antiseptic rinse at all 3 concentrations of 0.5%, 1.25%, and 1.5% completely inactivated SARS-CoV-2. The H O solutions at concentrations of 1.5% and 3.0% showed minimal viricidal activity after 15 seconds and 30 seconds of contact time.
SARS-CoV-2 virus was completely inactivated by PVP-I oral antiseptic rinse in vitro, at the lowest concentration of 0.5 % and at the lowest contact time of 15 seconds. Hydrogen peroxide at the recommended oral rinse concentrations of 1.5% and 3.0% was minimally effective as a viricidal agent after contact times as long as 30 seconds. Therefore, preprocedural rinsing with diluted PVP-I in the range of 0.5% to 1.5% may be preferred over hydrogen peroxide during the COVID-19 pandemic.
评估临床推荐浓度和接触时间的过氧化氢（H₂O₂）和聚维酮碘（PVP-I）口腔抗菌漱口水对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的体外灭活效果。
在进行测试之前，通过在 Vero 76 细胞中培养，制备 SARS-CoV-2、美国-WA1/2020 株病毒储备液。制备的病毒储备液的培养基为含 2%胎牛血清（FBS）和 50μg/mL 庆大霉素的最低必需培养基（MEM）。包含 PVP-I 口腔冲洗液和 H₂O₂水溶液的测试化合物直接与病毒溶液混合，使测试化合物的最终浓度为 50%，病毒溶液的最终浓度为 50%。因此，PVP-I 以 0.5%、1.25%和 1.5%的浓度进行测试，H₂O₂以 3%和 1.5%的浓度进行测试，以代表临床推荐浓度。乙醇和水作为标准阳性和阴性对照平行进行评估。所有样品的接触时间为 15 秒和 30 秒。然后通过标准终点稀释测定法定量测定每个样品中的存活病毒，并计算每个化合物与阴性对照的对数减少值。
在 15 秒和 30 秒接触时间后，所有 3 种浓度（0.5%、1.25%和 1.5%）的 PVP-I 口腔抗菌漱口水均完全灭活 SARS-CoV-2。在 15 秒和 30 秒接触时间后，浓度为 1.5%和 3.0%的 H₂O₂溶液显示出最小的杀病毒活性。
SARS-CoV-2 病毒在体外被 PVP-I 口腔抗菌漱口水完全灭活，最低浓度为 0.5%，最短接触时间为 15 秒。在接触时间长达 30 秒的情况下，推荐用于口腔冲洗的过氧化氢浓度为 1.5%和 3.0%时，作为杀病毒剂的效果最小。因此，在 COVID-19 大流行期间，与过氧化氢相比，预处理时在 0.5%至 1.5%范围内使用稀释的 PVP-I 冲洗可能更优。
